Healthcare Industry News: radiation dermatitis
News Release - May 17, 2006
Carrington Appoints New Vice President, Corporate Sales & Marketing
IRVING, Texas, May 17 (HSMN NewsFeed) -- Carrington Laboratories, Inc. (Nasdaq: CARN ) today announced that Doug Golwas has joined the Company as vice president, corporate sales and marketing. Golwas will assume the corporate leadership position for sales and marketing activities across Carrington's product lines, which includes its own-branded wound management and skin care products, nutraceuticals sold under the AloeCeuticals® label, raw materials for the nutraceutical and cosmetic industries, and specialty manufacturing services.Golwas was previously vice president of sales, marketing, business development and customer operations for Berkshire Corporation, a privately- held global leader in contamination control and removal products servicing the pharmaceutical, medical device, biotechnology and electronics markets. Prior to joining Berkshire in 1998, Golwas led the international marketing efforts for Kimberly-Clark's Tecnol industrial products under its professional healthcare division.
"Doug's expertise in driving dynamic sales and profit growth is evidenced by his fourteen-year record of success in the highly competitive medical, dental, pharmaceutical, medical device, biotech and electronics markets," said Carlton Turner, Carrington's president and CEO. "With his strength in global sales development and opening strategic new markets, Doug is a key addition to our management team and we are delighted that he has joined us. He is a proven achiever, and we expect his contributions to our top and bottom line growth to be significant."
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol® and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed May 4, 2006.
Source: Carrington Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
